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Abstract: Paclitaxel is a widely used chemotherapeutic agent; however, its therapeutic index 
is limited by low tumor exposure and high systemic exposure. Paclitaxel poliglumex (PPX) 
is macromolecular drug conjugate that links paclitaxel with a biodegradable polymer, poly-
L-glutamic acid. PPX enhances tumor exposure by taking advantage of the hyperpermeable 
vasculature and suppressed lymphatic clearance characteristic of tumor tissue. The release 
of paclitaxel from the polymeric backbone is, at least in part, dependent on the metabolism 
of PPX by the lysosomal protease cathepsin B, which is upregulated in many tumor types. 
Retrospective analysis of clinical data from two phase III trials in advanced lung cancer sug-
gests that PPX activity may be modulated by estradiol: a trend toward improved survival in 
the PPX arm compared with the control arm was observed in female, but not in male patients. 
Estrogens are known to induce cathepsin B activity; cathepsin B-mediated proteolysis is a key 
enzymatic processing step in PPX metabolism. The association between estrogens and PPX 
activity is being further explored in ongoing preclinical studies. An addition phase III trial will 
enroll women with advanced NSCLC to prospectively evaluate the efﬁ  cacy of PPX in relation 
to pre- and post-menopausal estrogen levels.
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Introduction
Paclitaxel, one of the most widely used cytotoxic agents, induces mitotic arrest and 
apoptosis in proliferating cells by targeting tubulin, a component of the mitotic spindle 
(Manfredi et al 1982; Bhalla 2003). Like other small, hydrophobic agents, paclitaxel 
binds extensively to plasma proteins, and its pharmacokinetic proﬁ  le is characterized by 
a short plasma elimination half-life with a broad tissue distribution (Kumar et al 1993; 
Sonnichsen and Relling 1994). These unfavorable pharmacokinetic characteristics are 
associated with limited tumor and high systemic tissue exposure, thus reducing the 
therapeutic index of paclitaxel. In addition, the intravenous administration of hydro-
phobic agents requires the use of solubilizing agents, such as Cremophor® EL/ethanol. 
Cremophor EL is a biologically and pharmacologically active compound, and its use 
is associated with acute hypersensitivity reactions (Gelderblom et al 2001).
As a chemotherapeutic agent, paclitaxel is indicated for ﬁ  rst-line platinum-based 
combination treatment in advanced ovarian carcinoma and non-small cell lung 
carcinoma (NSCLC). Paclitaxel is also indicated for second-line treatment of ovar-
ian and breast carcinoma. The toxicity proﬁ  le of paclitaxel is characterized by bone 
marrow suppression, neuropathy, and alopecia (Rowinsky and Donehower 1995). 
Hematological toxicities can be managed with the prophylactic use of hematopoietic 
growth factors, particularly in patients at risk for myelosuppression (Markman 2003). 
Also patients require pretreatment corticosteroids and anti-histamines to prevent acute 
hypersensitivity reactions. The administration of paclitaxel typically requires a 3-hour International Journal of Nanomedicine 2006:1(4) 376
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infusion, on a 3-week schedule. Weekly taxane schedules are 
currently being investigated, as more frequent administration 
at a lower dose may reduce myelosuppression and febrile 
neutropenia (Seidman 2005).
Biodegradable,macromolecular polymer–drug conju-
gates allow for a more sustained and targeted delivery 
of chemotherapeutic agents. The performance of these 
nano-sized (5–100 nm) polymer-based pharmaceuticals 
is inﬂ  uenced by morphological characteristics, surface 
chemistry, and molecular weight (Langer 1998; Bala et al 
2004). When well-designed, these polymer–drug conju-
gates preferentially deliver active drug to tumor tissue, 
limiting exposure of normal tissues. In addition, the slow 
release of drug from the polymer yields lowers peak plasma 
concentrations of active drug. Paclitaxel poliglumex, a 
polymer–drug conjugate of paclitaxel and poly-L-glutamic 
acid, was designed to enhance the therapeutic index of 
paclitaxel by improving its pharmacokinetic proﬁ  le, and 
to provide a water-soluble alternative to the standard pacli-
taxel formulation.
Paclitaxel poliglumex
A macromolecular polymer-drug 
conjugate
Paclitaxel poliglumex (PPX) is a polymer–drug conjugate 
that links paclitaxel to a biodegradable polymeric backbone 
consisting of L-glutamic acid residues (Singer et al 2005). 
Paclitaxel is conjugated by ester linkage to the γ-carboxylic 
acid side chains of poly-L-glutamic acid. Because the con-
jugation site is through the 2' hydroxyl of paclitaxel, a site 
crucial for tubulin binding, conjugated paclitaxel does not 
interact with β-tubulin and is biologically inactive (Gueritte-
Voegelein et al 1991). The median molecular weight of PPX 
is 38.5 kDa. Conjugated paclitaxel represents approximately 
36% by weight of PPX, equivalent to about one paclitaxel 
ester linkage per 11 glutamic acid units (Figure 1).
The rate of release of paclitaxel from PPX by hydrolysis 
in buffered saline solution and in mouse or human plasma was 
evaluated. Incubation of PPX in buffered saline or plasma 
for 24 hours at 37°C showed that less than 14% of the bound 
paclitaxel had been hydrolyzed. This indicates that PPX is 
relatively resistant to plasma esterases and is unlikely to 
release substantial amounts of paclitaxel in the circulation, 
even with prolonged clearance times.
The characteristics of PPX were evaluated using gel-
permeation chromatography in an organic mobile phase. 
When combined with multiple angle laser-light scattering 
and reﬂ  ective index detection, the elution proﬁ  le provides 
information on the apparent average molecular weight and 
polydispersity of the polymer. Nuclear magnetic spectros-
copy conﬁ  rmed the conjugation of paclitaxel to the γ and α 
positions of polyglutamate. Spectral changes were consistent 
with conjugation through the paclitaxel 2'- position with 
additional minor amounts of conjugation in the 7'-position. 
The distribution of paclitaxel on the polyglutamate back-
bone was studied through limited proteolysis of PPX with 
pronase. The resulting peptide mixtures were analyzed by 
reverse-phase HPLC and mass spectrometry. A wide range 
of peptide species were observed in the enzyme digest; they 
can be described as (Glu)n-(paclitaxel)x, where n = 1–20 and 
x = 1–6. This is in good agreement with a distribution of 
paclitaxel that would be expected if the conjugation occurred 
in a non-directed fashion (Singer et al 2005).
Tumor accumulation
Polymer–drug conjugates passively accumulate in tumor 
tissue by taking advantage of the hyperpermeable tumor 
vasculature and reduced lymphatic clearance, a phenomenon 
known as the enhanced permeation and retention (EPR) effect. 
Tumor vasculature is more permeable to macromolecules 
than normal vasculature because of structural differences 
between the neovasculature in tumors and the mature vascu-
lature in normal organs (Gerlowski and Jain 1986; Roberts 
and Palade 1997). The paucity of lymphatic vessels in tumor 
tissue allows the retention of these macromolecules in the 
interstitial space, resulting in a 10- to 100-fold increase in 
intra-tumoral drug concentrations when compared with an 
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Figure 1 Schematic representation of PPX. The structure shown is illustrative of a 
fragment of the molecule, but speciﬁ  c conjugation sites are not implied. On average 
there are approximately 10.4 non-conjugated monomer glutamic acid units (a + b) 
for every molecule conjugated to a paclitaxel molecule (y). The a-poly-L-glutamic 
degree of polymerization and the number of conjugation sites with paclitaxel are 
variable within the drug substance’s speciﬁ  cations.International Journal of Nanomedicine 2006:1(4) 377
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equivalent dose of the drug given conventionally (Matsumura 
and Maeda 1986; Greish et al 2003). Macromolecules, char-
acterized by high molecular weight, cannot be internalized 
into cells by simple diffusion; instead, macromolecules enter 
cells through endocytosis. Following internalization through 
endocytosis, polymer–drug conjugates are transported via 
the endosomal compartment to the lysosomes. Active drug 
is released through degradation by lysosomal enzymes, fol-
lowed by diffusion of the active agent into the cytoplasm or 
nucleus (Figure 2) (Duncan 1992, 2003).
To take advantage of the EPR effect, macromolecules 
have to remain in circulation for at least 6 hours (Matsumura 
and Maeda 1986). Clinical plasma pharmacokinetics of 
PPX show a biphasic decline with a prolonged distribution 
phase, and an elimination phase with a long terminal half-
life. Following a 10- to 30-minute infusion of single-agent 
PPX, plasma concentrations of conjugated taxanes decline 
biphasically (Figure 3A). The distribution phase is prolonged 
and the elimination phase, which appears approximately 
48 hours after drug administration, is characterized by a 
long terminal half-life, t1/2,z, of 108–261.5 hours (Bernareggi 
2005). PPX is relatively stable in circulation; the area under 
the curve (AUC) of unconjugated paclitaxel is 1%–2% of the 
AUC of conjugated paclitaxel. The total systemic exposure 
Nucleus
Macromolecular
polymer-drug conjugate
Lysosomal enzymes
Endocytosis
Endosome fuses with lysosome
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Intracellular release of drug
Figure 2 Internalization of macromolecules by endocytosis and release of active drug. Macromolecules are internalized through endocytosis. Enzymatic degradation of the 
polymeric backbone by lysosomal enzymes mediates the release of active drug.
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Figure 3A Clinical plasma pharmacokinetics. Plasma samples were collected from patients receiving PPX as a 10- to 30-minute infusion once every 3 weeks. Conjugated 
and unconjugated paclitaxel were measured by validated HPLC/MS methods. The plasma concentration of conjugated paclitaxel declines biphasically and is characterized by 
a prolonged distribution phase and an elimination phase with a long terminal half-life.International Journal of Nanomedicine 2006:1(4) 378
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to unconjugated paclitaxel is similar after administration of 
equivalent doses of PPX and standard paclitaxel; however, 
the Cmax values for paclitaxel are signiﬁ  cantly lower in 
patients treated with PPX (Figure 3B).
The prolonged circulation time of PPX facilitates tumor 
accumulation through the EPR effect, as was demonstrated 
in model animals (Singer et al 2005). To determine the 
pharmacokinetic proﬁ  le of PPX and its tissue distribution, 
female mice with subcutaneous B16 murine melanomas were 
given equivalent doses of tritium-labeled paclitaxel 40 mg/
kg iv, either as [3H]paclitaxel in Cremophor EL/ethanol or 
as [3H]paclitaxel poliglumex in phosphate buffer. Tumor 
samples were collected at regular intervals up to 144 hours 
after the injection, and the concentrations of PPX and pacli-
taxel were determined by LC/MS analysis. Tumor exposure 
of B16 melanomas to total taxanes was increased by a 
factor of 3 (Cmax) or factor of 12 (AUC) in mice treated with 
[3H]PPX compared with animals treated with [3H]paclitaxel 
(Table 1; Figure 4). Distribution of paclitaxel to the tumor 
was faster with [3H]paclitaxel, but overall tumor exposure 
to paclitaxel, with steady concentrations between 24 and 
120 hours, was higher after administration of [3H]PPX. In 
addition to tumor tissue, PPX also accumulates in tissues 
with abundant reticular endothelial systems through active 
phagocytosis (eg, liver, spleen).
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Figure 3B Schematic representation of the plasma pharmacokinetics of paclitaxel 
vs PPX (unconjugated paclitaxel). Total systemic exposure to PPX (unconjugated 
paclitaxel) and standard paclitaxel are similar;  however, Cmax of PPX (unconjugated 
paclitaxel) is lower than equivalent doses of standard paclitaxel.
Table 1 Preclinical tumor pharmacokinetics
Cmax 
(μg/g)
Tmax 
(h)
AUClast 
(μg h/g)
MRT 
(h)
[3H]PPX
  Total  taxanes 72.0 4 4547 51
  Paclitaxel 4.0 72 345 66
[3H]paclitaxel
  Total  taxanes 26.7 1.5 384 23
  Paclitaxel 22.4 1.5 261 17
Notes: Cmax, highest drug concentration; Tmax, time at which highest drug 
concentration occurs following administration;   AUClast, area under the drug 
concentration-time curve; MRT, mean retention time.
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Figure 4 Preclinical tumor pharmacokinetics. To determine the tissue pharmacokinetic proﬁ  le of PPX, female mice with subcutaneous B16 murine melanomas were given 
tritium-labeled paclitaxel 40 mg/kg intravenously, either as [3H]paclitaxel in polyoxyethylated castor oil/ethanol or [3H]PPX in phasophate buffer.  Samples were collected 
from 0 to 144 hours; the concentration of extractable taxanes was determined by HPLC/MS.International Journal of Nanomedicine 2006:1(4) 379
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Metabolism
Anti-tumor activity requires the release of paclitaxel from the 
conjugate through the proteolysis of the polymeric backbone. 
Initially, two PPX metabolites, monoglutamyl-paclitaxel 
isomers Glu-2'-TXL (2'-[L-γ-glutamyl]-paclitaxel) and 
Glu-7'-TXL (7'-[L-γ-glutamyl]-paclitaxel), were identiﬁ  ed 
in tumor tissue from B16 tumor-bearing mice exposed to 
[3H]-labeled PPX. Subsequent pharmacokinetic analysis 
indicated a gradual increase of [3H]-labeled PPX metabolites 
in tumor tissue, reaching Tmax at 72 hours post-administration. 
In comparison, administration of [3H]-paclitaxel resulted in a 
Tmax at 1.5 hours. The gradual accumulation of PPX in tumor 
tissue was associated with prolonged tumor exposure to PPX 
metabolites Glu-2'-TXL and paclitaxel. These observations 
demonstrate the intra-tumoral degradation of the poliglu-
tamate backbone of PPX in association with the release of 
paclitaxel (Singer et al 2005).
PPX biodegradation was further characterized in vitro and 
in vivo using qualitative and quantitative LC/MS analysis 
(Shaffer et al 2007). The intracellular, time-dependent gene-
ration of 5 PPX metabolites was observed in RAW 264.7 
monocytes as well as the human HT-29 colon adenocarcinoma 
and NCI-H460 non-small lung carcinoma cell lines. In cell-
free assays, mainly the carboxy exopeptidases, cathepsin B 
and X, could mediate PPX metabolism. In vitro, the release 
of conjugated paclitaxel was dependent on the activity of 
cathepsin B. Data from a cathepsin B deﬁ  cient animal model 
conﬁ  rmed that cathepsin B is an important in vivo mediator 
of PPX metabolism and the subsequent release of paclitaxel; 
however, other proteolytic pathways may contribute as well.
In normal physiological conditions, cathepsin B expres-
sion and activity is tightly regulated (Yan and Sloane 2003). 
In malignant tumors and premalignant lesions, cathepsin B 
expression is increased, which may also be associated with 
secretion and localization at the cell membrane (Poole et al 
1978; Spiess et al 1994; Linebaugh et al 1999). Both intra-
cellular and membrane-bound cathepsin B contributes to the 
degradation of the extracellular matrix, a crucial step in the 
process of tumor cell invasion (Szpaderska and Frankfater 
2001; Premzl et al 2003).
Clinical development
Performance status (PS) measures the impact of tumor-related 
symptoms and co-morbidities, such as co-existing illnesses 
and older age, on a patient’s functional status; poor PS is 
deﬁ  ned by a score of 2 or more on the Eastern Cooperative 
Oncology Group ECOG performance scale. In NSCLC, 
poor PS is associated with a poor prognosis and an increased 
vulnerability to chemotherapy-related toxicities (Sweeney 
et al 2001; Crinò et al 2002). In the absence of clinical trials 
enrolling signiﬁ  cant numbers of poor PS patients, no standard 
of care has been established for the treatment of patients with 
advanced NSCLC and poor PS. When considering treat-
ment options for patients with advanced NSCLC and poor 
PS, meaningful clinical beneﬁ  t is not only determined by 
improved survival, but also symptom relief and tolerability 
(Blackhall et al 2005). Two phase III studies evaluated the 
efﬁ  cacy and safety of PPX in chemotherapy-naïve patients 
with advanced NSCLC and a poor performance status. In 
STELLAR 3, PPX in combination with carboplatin was 
compared with paclitaxel in combination with carboplatin, 
and in STELLAR 4, PPX as a single agent was compared 
with physician’s choice of either gemcitabine or vinorelbine. 
A third phase III study, STELLAR 2, compared PPX with 
docetaxel in patients with relapsed/refractory NSCLC. The 
primary efﬁ  cacy endpoint for all three trials was survival, 
and PPX was shown to be as effective as current treatment 
options in NSCLC (Table 2).
Compared with docetaxel, PPX was associated with 
a favorable hematological toxicity proﬁ  le, reducing the 
incidence of severe neutropenia and infection (Table 3). 
The reduced hematologic toxicity was clinically relevant 
as patients in the PPX arm showed a signiﬁ  cant decrease 
in the requirement for supportive care (Figure 5). The non-
hematologic toxicity proﬁ  le of PPX is characterized by 
Table 2 PPX phase III efﬁ  cacy summary (no statistically 
signiﬁ  cant differences between the treatment arms were 
observed in STELLAR 2, 3, and 4)
STELLAR 3 PPX/Carbo Pac/Carbo
N 199 201
Median OS (mo) 7.8 7.9
1-yr survival 31% 31%
2-yr survival 13% 11%
STELLAR 4 PPX Gem or Vin
N 191 190
Median OS (mo) 7.3 6.6
1-yr survival 26% 26%
2-yr survival 15% 13%
STELLAR 2 PPX Docetaxel
N 422 416
Median OS (mo) 6.9 6.9
1-yr survival 25% 29%
2-yr survival 9% 12%
Abbreviations: Carbo, carboplatin; gem, gemcitabine; pac, paclitaxel; vin, 
vinorelbine.International Journal of Nanomedicine 2006:1(4) 380
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minimal hair loss, a distressing side-effect of chemotherapy 
associated with a lowered self-esteem and a negative body 
image. In general, PPX-related non-hematologic severe 
(grade 3 or 4) adverse events are similar to those of other 
taxanes, with dose-related neuropathy as the most clinically 
important issue (Langer et al 2005; O’Byrne 2005a, b).
Future directions
In the phase III studies, chemo-naïve patients receiving 
PPX had similar overall survival compared with patients in 
the control arms. However, in STELLAR 4, a trend towards 
improved survival was noted for female patients receiving 
PPX compared with female patients in the control arm: 
49 women received PPX and 56 received gemcitabine or 
vinorelbine; the median survival for females in the PPX 
arm was 312 days compared with 209 days for females in 
the control arm (log rank p = 0.069; hazard ratio = 0.65). 
In contrast, survival was similar for male patients, regard-
less of treatment, indicating a potential gender-speciﬁ  c 
beneﬁ  t associated with PPX for the treatment of lung 
cancer (Ross 2006).
The comparison of lung tumors from male and female 
patients has identiﬁ  ed various tumor characteristics that may 
affect tumor etiology in a gender-speciﬁ  c manner (Patel 2005; 
Thomas et al 2005). Particularly, lung tumorigenesis may be 
modulated depending on exposure to estrogen. An epide-
miologic link between estrogen exposure and incidence of 
Table 3 Hematologic toxicity proﬁ  le: PPX vs docetaxel 
(STELLAR 2)
PPX Docetaxel p value
Anemia, All 17% 26% 0.002
Grade 3/4a 5% 4% 0.865
Neutropenia 21% 44% <0.001
Grade 3/4a 14% 37% <0.001
Thrombocytopenia 7% 4% 0.077
Grade 3/4a 2% <1% 0.090
Febrile Neutropeniaa 2% 6% 0.002
Infection 25% 32% 0.032
Grade 3/4a 7% 11% 0.088
aReported adverse events.
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Table 4 Paclitaxel vs PPX
Characteristic Paclitaxel PPX
Solubility Requires toxic solubilizing agents Water-soluble
Administration 3- to 24-hr infusion with routine premedications 10- to 20-minute infusion, no routine premedication
Systemic exposure Yes Reduced Cmax: gradual paclitaxel release from inactive 
drug conjugate
Pharmacokinetics Short elimination half-life Prolonged distribution phase, elimination phase with 
long terminal half-life
Tumor selectivity No Passive tumor accumulation
NSCLC has been suggested in Japanese non-smoking women 
(Liu et al 2005). Younger, presumably pre-menopausal, 
women appear to have shorter survival than older women: 
in an analysis of patients with advanced NSCLC enrolled 
in Southwest Oncology Group (SWOG) trials, women over 
70 had a 34% 1-year survival compared with 11% for those 
under 45 (Albain et al 1991).
Estrogen-induced cell proliferation is a critical step 
in the etiology and progression of a variety of tumor 
types (Deroo and Korach 2006). The cellular response 
to estrogen is mediated by estrogen receptor alpha (ER-
alpha) and ER-beta. These receptor proteins function 
as ligand-dependent transcription factors and regulate 
the expression of genes implicated in cell cycle control, 
signal transduction, and cell survival (Frasor et al 2003; 
Edwards 2005). In animal models, estrogen plays a role 
in normal pulmonary physiology (Massaro and Massaro 
2004, 2006); adult females have a larger number of 
alveoli that are smaller in size, than males. This difference 
develops as animals reach sexual maturity and seems to 
be mediated mainly by estrogens (Massaro et al 1996). In 
vivo studies show that ER-beta is abundantly expressed 
in lung tissue and controls the transcription of platelet-
derived growth factor A (PDGF-A), which plays a pivotal 
role in alveolar formation, and granulocyte macrophage 
colony-stimulating factor (GM-CSF), a key regulator of 
surfactant homeostasis (Patrone et al 2003). ER-beta, and 
to a lesser extend ER-alpha, are expressed in lung tumors 
from both men and women; in a large series of surgically 
resected NSCLC tumors, ER-beta was detected in 45.8% 
of cases. Overexpression of ER-beta was signiﬁ  cantly 
more common in tumors from non-smokers (53.5%) than 
smokers (36.6%, p<0.004). Among non-smokers, higher 
ER-beta expression was observed signiﬁ  cantly more fre-
quently in female patients (58.3%) than in male patients 
(40.9%) (Wu et al 2005). The complex biological effects 
mediated by ERs involve communication between many 
proteins and signaling pathways, including lysosomal 
vesicle trafﬁ  cking.
Under the control of estrogen, intracellular trafﬁ  cking of 
cathepsin B may be altered in malignant tumors, resulting 
in the increased secretion of precursor and active forms of 
the enzyme (Poole et al 1978; Achkar et al 1990; Linebaugh 
et al 1999), its redistribution from perinuclear lysosomes to 
peripheral vesicles (Sloane et al 1994), and its association 
with the cell membrane (Spiess et al 1994; Sameni et al 
1995; Cavallo-Medved et al 2005). Cathepsin B localizes 
with other proteases at the tumor cell surface in caveolae, 
mediating cell-surface proteolytic events associated with 
invasion (Roshy et al 2003; Cavallo-Medved et al 2005). 
The abundance of cathepsin B in tumor tissue is relevant 
for the efﬁ  cient degradation of PPX. The interaction of 
lung cancer cells and inﬁ  ltrating immune cells, particularly 
phagocytic monocytes, can further promote tumor develop-
ment and metastasis. Homeostasis of human monocytes is 
regulated by estrogen, and monocytes are known to express 
both ER-alpha and ER-beta (Phiel et al 2005). Interest-
ingly, cathepsin X is upregulated in tumor-infiltrating 
immune cells, particularly in phagocytic monocytes (Kos 
et al 2005).
Summary
Factors limiting the therapeutic index of paclitaxel include 
low solubility, high systemic exposure, poor pharmacoki-
netic characteristics, and a lack of selective tumor uptake. 
The rationale for developing paclitaxel poliglumex (PPX), 
a macromolecular polymer–drug conjugate, was to improve 
standard chemotherapy with paclitaxel by overcoming some 
of these limitations (Table 4). Tumor pharmacokinetics 
show that tumor distribution is faster with paclitaxel, but 
overall tumor exposure is higher with PPX. The available 
data support a model in which PPX accumulates in tumor 
tissue through the EPR effect, followed by the cathepsin 
B-mediated release of paclitaxel.International Journal of Nanomedicine 2006:1(4) 382
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The cathepsin-mediated release of paclitaxel may have 
therapeutic implications as cathepsin B is upregulated in 
malignant cells, particularly during tumor progression. 
Estrogen may play an important role in lung tumor biology 
and is a modulator of cathepsin B activity. A possible associa-
tion between estrogen levels and PPX activity will be further 
explored in both preclinical and clinical studies.
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